Gabapentin Solution
Product Images NDC 82983-423

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82983-423). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajenat Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Oral Solution 1)

The image shows a pharmacokinetic formula for calculating creatinine clearance (CLCr) involving age, weight, and serum creatinine, with an adjustment factor for female patients. This formula is commonly used to assess kidney function in dosing considerations.*

FDA Label Image

Structure (Gabapentin Oral Solution 2)

Chemical structure of gabapentin, showing a cyclohexane ring attached to amino and carboxyl functional groups.*

FDA Label Image

Diagram1 (Gabapentin Oral Solution 3)

A line graph showing the mean pain score over weeks comparing Gabapentin 3600 mg/day to placebo. The x-axis represents weeks from baseline to 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 9, with scores decreasing more for Gabapentin than placebo.*

FDA Label Image

Diagram2 (Gabapentin Oral Solution 4)

A line graph depicting mean pain scores over 7 weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin groups show decreasing pain scores over time compared to placebo.*

FDA Label Image

Diagram3 (Gabapentin Oral Solution 5)

This bar chart compares the percentage results from two separate studies (Study 1 and Study 2) involving Gabapentin (GBP) at different dosages versus placebo (PBO). Study 1 shows 12% for placebo and 29% for GBP 3600, while Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Significant p-values indicating statistical differences are noted above the bars.*

FDA Label Image

Diagram4 (Gabapentin Oral Solution 6)

A scatter plot showing the percentage difference in an unspecified variable on the y-axis against daily dose in mg on the x-axis for Gabapentin. Data points from three different studies (Study a, Study b, Study c) are indicated by different symbols and shades, plotted at daily doses of approximately 600, 900, 1200, and 1800 mg with differences ranging from about 7% to 18%.*

FDA Label Image

Bottle (Label)

Gabapentin Oral Solution 250 mg/5 mL in a 16 fl. oz. (470 mL) bottle distributed by Ajenat Pharmaceuticals LLC. The label indicates prescription use only, storage conditions between 2° to 8°C, and instructs to keep out of reach of children. It includes a barcode and pharmacist dispensing instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.